Lexapro Related Published Studies
Well-designed clinical trials related to Lexapro (Escitalopram)
Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. [2009.09]
Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. [2009.07]
Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). [2009.04.07]
Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. [2009.04]
Superiority of escitalopram to paroxetine in the treatment of depression. [2009.04]
Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. [2009.03]
The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. [2009.03]
Escitalopram: an open-label study of bereavement-related depression and grief. [2009.02]
Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. [2009.01.21]
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. [2009.01]
Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. [2009]
No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter. [2008.12.15]
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. [2008.12]
[Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression] [2008.11]
Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. [2008.11]
Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. [2008.10.15]
Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. [2008.10.03]
Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. [2008.09]
Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. [2008.06]
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. [2008.05.28]
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. [2008.05]
Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. [2008.04]
An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients. [2008.04]
Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. [2008.03]
Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. [2008.03]
Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. [2008.03]
Escitalopram in specific phobia: results of a placebo-controlled pilot trial. [2008.03]
Escitalopram effects on insula and amygdala BOLD activation during emotional processing. [2008.03]
Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. [2008.02.15]
Escitalopram in the acute treatment of depressed patients aged 60 years or older. [2008.01]
Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. [2008.01]
High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. [2008.01]
Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. [2008]
Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data. [2008]
Bioequivalence of two commercial preparations of escitalopram oxalate/clonazepam using a liquid chromatography-electrospray mass spectrometry method. [2008]
An open-label trial of escitalopram in children and adolescents with social anxiety disorder. [2007.12]
Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial. [2007.10]
Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. [2007.10]
Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. [2007.10]
Escitalopram prevents relapse in older patients with major depressive disorder. [2007.07]
A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. [2007.07]
Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. [2007.07]
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. [2007.07]
An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. [2007.07]
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. [2007.06]
Escitalopram prevents relapse of obsessive-compulsive disorder. [2007.05]
Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. [2007.04]
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. [2007.04]
Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. [2007.03]
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. [2007.02]
Escitalopram in the treatment of anxiety symptoms associated with depression. [2007]
Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. [2007]
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). [2007]
Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. [2006.11]
Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. [2006.10]
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. [2006.10]
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. [2006.07]
Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. [2006.07]
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. [2006.05]
A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. [2006.05]
A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. [2006.03]
An Open Trial of Adjunctive Escitalopram in Bipolar Depression. [2006.01]
Escitalopram in the long-term treatment of major depressive disorder in elderly patients. [2006]
Does rTMS Hasten the Response to Escitalopram, Sertraline, or Venlafaxine in Patients With Major Depressive Disorder? A Double-Blind, Randomized, Sham-Controlled Trial. [2005.12]
The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. [2005.12]
The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. [2005.09]
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. [2005.08]
The effect of escitalopram on sleep problems in depressed patients. [2005.07]
A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. [2005.06]
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. [2005.05]
Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. [2005.04]
A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. [2005.04]
Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. [2005.04]
Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. [2005.03]
Effects of desipramine and escitalopram on postprandial symptoms induced by the nutrient drink test in healthy volunteers: a randomized, double-blind, placebo-controlled study. [2005]
Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. [2005]
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. [2005]
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. [2004.09]
Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. [2004.09]
Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses. [2004.09]
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. [2004.05]
Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. [2004.04]
Escitalopram continuation treatment prevents relapse of depressive episodes. [2004.01]
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. [2004]
Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. [2004]
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. [2004]
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. [2003.11]
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. [2003.07]
An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. [2003.04]
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. [2002.05]
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. [2002.04]
Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. [2001.05]
Well-designed clinical trials possibly related to Lexapro (Escitalopram)
Antidepressant study design affects patient expectancy: a pilot study. [2009.09.07]
Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression. [2009.08]
Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. [2009.07]
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. [2009.07]
Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. [2009.07]
A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. [2009.07]
Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. [2009.06]
Effect of a single dose of citalopram on amygdala response to emotional faces. [2009.06]
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. [2009.06]
|
